BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36912648)

  • 21. Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
    Fujita A; Kimura K; Yokoyama S; Jin W; Wachino J; Yamada K; Suematsu H; Yamagishi Y; Mikamo H; Arakawa Y
    PLoS One; 2015; 10(11):e0142366. PubMed ID: 26539828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypic and genotypic detection of ESBL mediated cephalosporin resistance in Klebsiella pneumoniae: emergence of high resistance against cefepime, the fourth generation cephalosporin.
    Grover SS; Sharma M; Chattopadhya D; Kapoor H; Pasha ST; Singh G
    J Infect; 2006 Oct; 53(4):279-88. PubMed ID: 16488476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures].
    Zarakolu P; Metan G; Hasçelik G; Akova M
    Mikrobiyol Bul; 2007 Oct; 41(4):579-84. PubMed ID: 18173077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?
    Moland ES; Sanders CC; Thomson KS
    J Clin Microbiol; 1998 Sep; 36(9):2575-9. PubMed ID: 9705395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology.
    Queenan AM; Foleno B; Gownley C; Wira E; Bush K
    J Clin Microbiol; 2004 Jan; 42(1):269-75. PubMed ID: 14715764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of resistance and antibacterial susceptibility in extended-spectrum β-lactamase phenotype Klebsiella pneumoniae and Klebsiella oxytoca isolated between 2000 and 2010 in Japan.
    Sato T; Hara T; Horiyama T; Kanazawa S; Yamaguchi T; Maki H
    J Med Microbiol; 2015 May; 64(Pt 5):538-543. PubMed ID: 25813819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE.
    Tenover FC; Raney PM; Williams PP; Rasheed JK; Biddle JW; Oliver A; Fridkin SK; Jevitt L; McGowan JE;
    J Clin Microbiol; 2003 Jul; 41(7):3142-6. PubMed ID: 12843054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
    Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.
    Wang P; Hu F; Xiong Z; Ye X; Zhu D; Wang YF; Wang M
    J Clin Microbiol; 2011 Sep; 49(9):3127-31. PubMed ID: 21752977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of three different methods for the presumptive detection of ESBL production in ceftazidime-resistant strains of Klebsiella pneumoniae.
    Palasubramaniam S; Parasakthi N
    Malays J Pathol; 2001 Dec; 23(2):73-8. PubMed ID: 12166595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of extended spectrum beta lactamase and molecular detection of blaTEM, blaSHV and blaCTX-M genotypes among Gram negative bacilli isolates from pediatric patient population in Gaza strip.
    El Aila NA; Al Laham NA; Ayesh BM
    BMC Infect Dis; 2023 Feb; 23(1):99. PubMed ID: 36803466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence, molecular characterization, and phenotypic confirmation of extended-spectrum beta-lactamases in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca at the Radboud University Nijmegen Medical Centre in The Netherlands.
    Sturm PD; Bochum ET; van Mook-Vermulst SV; Handgraaf C; Klaassen T; Melchers WJ
    Microb Drug Resist; 2010 Mar; 16(1):55-60. PubMed ID: 20001741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of cefepime, cefotaxime, ceftazidime, and aztreonam against extended-spectrum-producing isolates of Klebsiella pneumoniae and Escherichia coli from Chilean hospitals.
    Zemelman C; Bello H; Domínguez M; González G; Mella S; Zemelman R
    Diagn Microbiol Infect Dis; 2001; 40(1-2):41-3. PubMed ID: 11448562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonal spread of CTX-M-15-producing Klebsiella pneumoniae in a Croatian hospital.
    Vranic-Ladavac M; Bosnjak Z; Beader N; Barisic N; Kalenic S; Bedenic B
    J Med Microbiol; 2010 Sep; 59(Pt 9):1069-1078. PubMed ID: 20576749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
    Castanheira M; Mills JC; Costello SE; Jones RN; Sader HS
    Antimicrob Agents Chemother; 2015; 59(6):3509-17. PubMed ID: 25845862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N
    Ourghanlian C; Soroka D; Arthur M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals.
    Castanheira M; Doyle TB; Mendes RE; Sader HS
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro selection of variants resistant to beta-lactams plus beta-lactamase inhibitors in CTX-M beta-lactamases: predicting the in vivo scenario?
    Ripoll A; Baquero F; Novais A; Rodríguez-Domínguez MJ; Turrientes MC; Cantón R; Galán JC
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4530-6. PubMed ID: 21788458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.
    Tofteland S; Haldorsen B; Dahl KH; Simonsen GS; Steinbakk M; Walsh TR; Sundsfjord A;
    J Clin Microbiol; 2007 Jan; 45(1):199-205. PubMed ID: 17079502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.